The Paediatric Rheumatology INternational Trials Organisation (PRINTO) is a not for profit, non governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996. The coordinating centre is based in Genova. PRINTO initially included 14 European countries (95 countries and 730 centres worldwide with 2072 members today), with the goal to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres, international clinical trials and/or outcome standardisation studies in children with paediatric rheumatic diseases (PRD).
Via Gaslini, 5
Genova
Liguria
16147
Italy

Paediatric Rheumatology INternational Trials Organisation (PRINTO)

The Paediatric Rheumatology INternational Trials Organisation (PRINTO) is a not for profit, non governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996. Including initially 14 European countries, the organization counts now on the cooperation of 2072 members from 730 centres in 95 countries worldwide. PRINTO has the goal to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres, international clinical trials and/or outcome standardisation studies in children with paediatric rheumatic diseases (PRD).

The coordinating centre is based in Genoa.
To learn more about PRINTO click here
To download the PRINTO brochure click here


IN THE SPOTLIGHT

  • 14-JUN-2024
    PRINTO/PRCSG/Pfizer Manuscript on safety and efficacy results of tofacitini...
    More details...
  • 13-MAR-2024
    European Workshop for Rheumatology Research (EWRR) - 43rd edition
    View website of the event...
  • 10-DEC-2023
    PReS/PRINTO Research Grants | 2023 Call for proposals - by February 15th, 2...
    More details...
  • 14-MAY-2022
    PRINTO/PRCSG/Pfizer Tofacitinib manuscript authors'reply published in the L...
    More details...
  • 14-FEB-2022
    The MeRITA website has gone live and is now online
    More details...
  • 11-NOV-2021
    PRINTO/PRCSG/Pfizer Tofacitinib manuscript published in the Lancet
    More details...
  • 15-MAR-2019
    EPOCA manuscript published in Lancet Child Adolesc Health!
    Paper details...
  • 04-FEB-2019
    First results of the PRINTO Consensus for new JIA Classification published!
    Paper details...
  • 16-AUG-2018
    Consensus proposal for Taxonomy of AIDs: manuscript published on ARD
    Paper details...
  • 24-MAY-2018
    Subcutaneous Abatacept in poly JIA Manuscript published in Arthritis & Rheu...
    More details...

PROJECTS

  • conect4children (c4c)
    PRINTO is partner of the "conect4children" (c4c) initiative, the collaborative network for European clinical trials for children, (c4c) a consortium that aims to enhance the competitiveness of Europe as a critical region for developing medicines for children.
    Learn More
  • Liaisons with pharmaceutical companies
    PRINTO is working with pharmaceutical companies as advisor for trials planning, centre selection, data collection, data analysis and interpretation…
    Learn More
  • The STARS Trial
    The comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS trial (STARS) is a new interventional trial aiming to investigate whether an early aggressive therapeutic intervention in children with JIA, based on the initial start of synthetic and biologic DMARDs (Step-down strategy), is superior to an approach based on treatment escalation conducted following the treat-to-target principle (Step-up strategy).
    Learn More
  • The JIA classification study
    The PRINTO Evidence-based Revision of the International League Against Rheumatism (ILAR) Classification criteria for juvenile idiopathic Arthritis.
    Learn More
  • The KIWI study
    Retrospective-prospective, observational, descriptive and multicenter study of patients with KD for the comparison and performance of Kobayashi and Kawanet IVIg resistance scores in a multi-centric European and North Indian cohort of Kawasaki disease.
    Learn More
  • CEST-JIA
    The study is aimed to evaluate, through a pragmatic trial, safety and efficacy of switching from the adalimumab and etanercept originator molecules versus their biosimilar competitors and vice-versa in children with JIA in clinical remission on anti-TNF medication.
    Learn More
  • Eurofever
    The PReS Autoinflammatory Diseases’ Working Group, in collaboration with PRINTO, set up a a web-based international registry for Autoinflammatory diseases.
    Learn More
  • Cross-cultural adaptation and validation of LoSQI in JLS
    Cross-cultural adaptation and validation of the Localised Scleroderma Quality of Life Instrument (LoSQI) in juvenile localised scleroderma (JLS) is a multicentre study of the PRES scleroderma working party in collaboration with members of the CARRA scleroderma working group.
    Learn More
  • The METAPHOR project
    The project named "OptiMizing trEatment in systemic juvenile idiopaThic Arthritis (sJIA) and macroPHage activation syndrOme (MAS)/secondaRy hemophagocytic lymphohistiocytosis (HLH), (METAPHOR), is winner of the 2021 PReS/PRINTO call for grants and has the aim to provide an overview of the real-life experience in sJIA and MAS/sHLH treatment through a survey involving the pediatric rheumatology centers part of the PReS/PRINTO networks.
    Learn More
  • The CREATE trial
    Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroids
    Learn More
  • PharmaChild
    PRINTO and PRES are conducting a pharmacovigilance project which aims at observing children with JIA for 3-10 years undergoing treatment with MTX or biologic agents in order to collect moderate, severe or serious adverse events occurred.
    Learn More
  • The HyperPED-COVID Registry
    A joined PReS, ESID, ISSAID, ERN-RITA and PRINTO network’s effort has been started with the aim to buid a registry of children and young adults who have developed serious inflammatory condition in temporal association with COVID-19 in the community.
    Learn More
  • The DAISY study
    The DAISY study (Applicability of standardized ultrasound examination to estimate disease activity in combination with JADAS and inflammation markers in JIA patients) aims to investigate sensitivity and predictive value of the multi-biomarker panel and to evaluate if it could be applied in limited number of joints in patients with oligo and polyarticular JIA course as a new disease activity tool and outcome measure.
    Learn More
  • The MeRITA project
    The MeRITA meta-data registry will collect in aggregated fashion the Common Data Elements (CDEs) of the single participating registries.
    Learn More
  • PAPA - Can trial
    A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome
    Learn More

CERTIFICATIONS

This website uses cookies. By continuing to browse the website you are agreeing to our use of cookies. Learn more   Accept cookies